Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498375 | 0.86 | CTRB1 (0.68) | CTRB1HDAC6ELANEALDH1A1GLS | |
| SCHEMBL6497237 | 0.75 | CTRB1 (0.55) | CTRB1HDAC6ELANEPOLBTP53 | |
| SCHEMBL6803206 | 0.73 | CTRB1 (0.52) | CTRB1HDAC6ELANE | |
| SCHEMBL6506565 | 0.71 | ELANE (0.53) | CTRB1HDAC6ELANEALDH1A1KMT2A | |
| SCHEMBL27355463 | 0.70 | CTRB1 (0.38) | CTRB1ALDH1A1NPC1POLBGLS | |
| SCHEMBL6498652 | 0.70 | CTRB1 (0.49) | CTRB1HDAC6ELANEALDH1A1KMT2A | |
| SCHEMBL6499627 | 0.69 | CTRB1 (0.47) | CTRB1ELANEALDH1A1NPC1KMT2A | |
| SCHEMBL6496069 | 0.69 | ELANE (0.50) | CTRB1HDAC6ELANEALDH1A1NPC1 | |
| SCHEMBL6504081 | 0.68 | ELANE (0.67) | CTRB1HDAC6ELANEALDH1A1 | |
| SCHEMBL6498365 | 0.67 | CTRB1 (1.00) | CTRB1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | CTRB1 2628/4885HDAC6 634/4885ELANE 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.